Prihlásiť sa Zaregistrujte sa zadarmo

Návratnosť imania spoločnosti NeuroVive Pharmaceutical AB

Aká je hodnota metriky Návratnosť imania spoločnosti NeuroVive Pharmaceutical AB?

Hodnota metriky Návratnosť imania spoločnosti NeuroVive Pharmaceutical AB je -69.63%

Aká je definícia metriky Návratnosť imania?



Návratnosť imania (Return on equity - ROE) je rentabilita vlastného imania. Vypočíta sa vydelením čistého príjmu za fiškálny rok vlastným imaním.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Návratnosť imania spoločností v sektore Miscellaneous sektor na LSE v porovnaní so spoločnosťou NeuroVive Pharmaceutical AB

Čomu sa venuje spoločnosť NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Firmy s metrikou návratnosť imania podobnou spoločnosti NeuroVive Pharmaceutical AB